Table 1.

FDA approved inflammasome-related drugs and their applications

Drug name	Target	Year	Initial applications	Recent applications	Most common adverse reactions	BLA
Anakinra	IL-1	2001	RA	CAPS, DIRA	Injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain (incidence ≥ 5%)	103950
Rilonacept	IL-1	2008	CAPS	FCAS, MWS	Injection-site reactions and upper respiratory tract infections	125249
Canakinumab	IL-1β	2009	CAPS	FCAS, MWS	Sopharyngitis, diarrhea, influenza, headache, and nausea	125319

RA rheumatoid arthritis, CAPS cryopyrin-associated periodic syndromes, DIRA deficiency of interleukin-1 receptor antagonist, FCAS Familial Cold Autoinflammatory Syndrome, MWS Muckle-Wells Syndrome